Dr. Christopher Lock, M.D. Ph.D.
diagnose early Advisor & Ms Clinical Lead At Stanford
King’s College, University of London
Westminster Hospital Medical School, University of London, Entrance Scholarship, MD
Imperial Cancer Research Fund Laboratories, Guy’s and King’s College
Hospital, University of London, PhD
Internal Medicine / Neurology Jul.1993-Jun.1997 Stanford University Medical Center
Neuroimmunology Fellow / Clinical Instructor Jul.1997-Jun.2000 Department of Neurology, Stanford Supervisor: Dr. Larry Steinman Funding: National Multiple Sclerosis Society
Dr. Christopher Lock has dedicated his career to understanding the basic science underlying Multiple Sclerosis and to caring for patients with Multiple Sclerosis. Over a career of more than twenty years at Stanford University and the Palo Alto Medical Foundation as a clinician and basic science researcher, Dr. Lock has published in prestigious journals such as the Nature Medicine, taught medical students and neurology residents and fellows, worked at a pharmaceutical start-up, and has been an investigator on multiple grants focused on both treatment and the basic science of Multiple Sclerosis.
Sutter Neuroscience Research Consortium 2014-2015
Peninsula Coastal Lead Neuroscience Research Advisory Board 2014-2015
Sutter Health, East Bay Neuroscience Institute Clinical Research Sites for the Network of Excellence in 2011
Neuroscience Clinical Trials (NEXT sites) (U10) NINDS Project Grant Application, Principle Investigator Sutter Health Data and Safety Monitoring Board (DSMB) 2009
Rituximab - neuromyelitis optica (NMO) study Dr. Bruce Cree, Chairperson, UCSF
Carantech Biosciences, Inc. 2006-2008 Founder: Dr. Claude Genain Multiple sclerosis drug and biomarker development Lead molecule at early pre-clinical stage of development Responsible for planning and conduct of scientific research, development of expression and purification methods, testing in EAE model. Planning and discussion of cGMP production, toxicology studies, and other requirements for IND application. Presentations to VCs and Angel investors.